Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed vs Pemetrexed + Carboplatin in Advanced NSCLC Patients with PS 2
NCT01836575Phase 3Completed
- Sponsor
- Instituto Nacional de Câncer José Alencar Gomes da Silva
- Start
- Apr 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Instituto Nacional de Câncer José Alencar Gomes da Silva. Primary endpoint: Overall Survival. Started Apr 2008; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01836575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01836575.